Amerikanische Gesellschaft für Hirudotherapie

Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look

Review published in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2016)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungRimsans J et al. · Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016

Abstract

Available options for the treatment of advanced heart failure have expanded to include the use of mechanical circulatory assist devices to improve quality of life in those both eligible and ineligible for heart transplant. Although there have been significant advancements in device technologies, anticoagulation protocols, and multidisciplinary team management, bleeding and thrombosis are the most common adverse effects. Management strategies for pump thrombosis and their outcomes vary considerably among mechanical circulatory support centers and include intensification of antithrombotic therapy (medical) and device exchange (surgical). We describe a successful case of medical therapy for pump thrombosis with bivalirudin monotherapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAntithrombinsExtracorporeal CirculationHeart FailureHirudinsHumansPeptide FragmentsRecombinant ProteinsThrombosis

Zusammenfassung

Available options for the treatment of advanced heart failure have expanded to include the use of mechanical circulatory assist devices to improve quality of life in those both eligible and ineligible for heart transplant.

Warum dies für die Hirudotherapie relevant ist

This article discusses the management of bleeding and thrombosis in patients with mechanical circulatory assist devices for advanced heart failure, noting that strategies for pump thrombosis vary among centers and include intensification of antithrombotic therapy (medical) and device exchange (surgical). The authors describe a successful case of medical therapy for pump thrombosis using bivalirudin monotherapy. The abstract makes no mention of hirudin, leeches, direct thrombin inhibition, leech-derived components, or hirudotherapy. Accordingly, no defensible connection to ASH's domain or the leech secretome can be drawn from this source alone; any relationship between bivalirudin and leech-derived anticoagulants would require external information not present in the abstract.

Zitation

Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look

Rimsans J et al. · Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsAnticoagulation CompoundsHemostasisHirudinOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.